More on: Optimal dose for stroke thrombolysis in Asians

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 9, 2012, Pages 1970-1971

  Ahmad, A ^a   Sharma, V K ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ASIAN; BRAIN ISCHEMIA; COMPARATIVE EFFECTIVENESS; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFECT; EUROPE; FIBRINOLYTIC THERAPY; HUMAN; LETTER; META ANALYSIS (TOPIC); NORTH AMERICA; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ASIAN CONTINENTAL ANCESTRY GROUP; HUMANS; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84865734098     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04836.x     Document Type: Letter

References (9)

1. Chuang MT, Chen WL, Sun MC. Optimal dose for stroke thrombolysis in Asians: low dose may be comparable to standard dose. J Thromb Hemost 2012; 10: 1270-5.
2. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997; 349: 1269-76.
3. Bonita R, Mendis S, Truelsen T, Bogousslavsky J, Toole J, Yatsu F. The global stroke initiative. Lancet Neurol 2004; 3: 391-3.
4. Brott TG, Haley EC Jr, Levy DE, Barsan W, Broderick J, Sheppard GL, Spilker J, Kongable GL, Massey S, Reed R, Marler JR. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90minutes. Stroke 1992; 23: 632-40.
5. Haley EC Jr, Levy DE, Brott TG, Sheppard GL, Wong MC, Kongable GL, Torner JC, Marler JR. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180minutes from onset. Stroke 1992; 23: 641-5.
6. Khatri P, Broderick JP, Pancioli AM. Risk of thrombolysis-associated intracerebral hemorrhage: the need to compare apples with apples. Stroke 2005; 36: 1109-10.
7. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, Albers GW, Kaste M, Marler JR, Hamilton SA, Tilley BC, Davis SM, Donnan GA, Hacke W, ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group, Allen K, Mau J, Meier D, del Zoppo G, De Silva DA et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375: 1695-703.
8. Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, Shinohara Y, Japan Alteplase Clinical Trial (J-ACT) Group. Alteplase at 0.6mg/kg for acute ischemic stroke within 3hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 2006; 37: 1810-5.
9. Sharma VK, Ng KW, Venketasubramanian N, Saqqur M, Teoh HL, Kaul S, Srivastava PM, Sergentanis T, Suwanwela N, Nguyen TH, Lawrence Wong KS, Chan BP. Current status of intravenous thrombolysis for acute ischemic stroke in Asia. Int J Stroke 2011; 6: 523-30.